AC Immune Stock Price, News & Analysis

AC Immune SA (NASDAQ: ACIU) announced its participation in the SVB Leerink 10th Annual Global Healthcare Conference from February 22-26, 2021. During the event, CEO Prof. Andrea Pfeifer will discuss the company’s precision medicine strategy and the promising interim Phase 1b/2a results of its anti-phospho-Tau vaccine candidate, ACI-35.030, developed in collaboration with Janssen Pharmaceuticals. The results indicated strong immunogenicity and safety in patients with early Alzheimer’s disease. A webcast of the presentation will be available on the company’s website.

AC Immune announced promising interim results from its Phase 1b/2a trial of the ACI-35.030 vaccine for early Alzheimer’s disease. The trial showed 100% of older patients generated high levels of anti-pTau antibodies post-vaccination, significantly exceeding pre-vaccination levels. The vaccine was safe and well-tolerated, with no adverse events reported. The findings support advancing ACI-35.030 into Phase 2/3 trials. This innovation highlights the potential for early intervention in Alzheimer’s, utilizing a cutting-edge vaccine formulation aimed at combating Tau pathology.

AC Immune SA (NASDAQ: ACIU) has initiated a first-in-human study of ACI-12589, a novel PET imaging tracer for Parkinson's disease (PD). This tracer aims to accurately detect pathological alpha-synuclein deposits in the brain, a hallmark of PD. Supported by the Michael J. Fox Foundation, results are expected in Q3 2021. In preclinical studies, ACI-12589 displayed improved sensitivity and specificity compared to previous candidates, potentially leading to earlier diagnosis and effective monitoring of disease progression.

AC Immune SA (NASDAQ: ACIU) announced advancements in its small molecule and antibody therapeutic programs targeting the NLRP3 inflammasome, crucial for neurodegenerative diseases like Alzheimer’s. The company has identified potent small molecule NLRP3 inhibitors, demonstrating significant biological activity in animal models. AC Immune plans to initiate in vivo proof-of-concept studies by year-end to evaluate CNS delivery and efficacy. Additionally, high-affinity antibodies that inhibit ASC-mediated inflammatory responses are under development. These pipeline advancements highlight AC Immune's commitment to addressing neurodegeneration.

AC Immune (NASDAQ: ACIU) received a USD 600,000 grant from Target ALS to advance a collaboration with Massachusetts General Hospital. The funding will accelerate the development of proprietary immuno-assays for detecting TDP-43, a protein linked to several neurodegenerative diseases, including ALS. These assays aim to improve early diagnostics, enabling targeted treatment strategies. AC Immune's CEO highlighted the potential of these assays and the ongoing development of an anti-TDP-43 therapeutic antibody. This positions the company as a leader in precision medicine for neurodegenerative conditions.

AC Immune has announced the appointment of Prof. June as a scientific leader, reinforcing the company's expertise in neurodegeneration. Prof. June is recognized globally for his work in immune tolerance and adoptive immunotherapy. This leadership change aligns with AC Immune's strategy to enhance its research capabilities, particularly in neurodegenerative diseases. The company is expected to leverage his knowledge to advance its pipeline and foster innovation.

AC Immune announces the appointment of Prof. Johannes R. Streffer as Chief Medical Officer, effective January 2021. With extensive experience in neurology and psychiatry, Prof. Streffer aims to enhance AC Immune's pipeline targeting neurodegenerative diseases. Previously at UCB Biopharma, he led advancements in neuroscience and clinical study design, particularly in Alzheimer’s disease. The company’s pipeline includes nine therapeutic candidates, with collaborations involving major pharmaceutical firms like Genentech and Eli Lilly.

AC Immune SA (NASDAQ: ACIU) reported Q3 2020 financial results, achieving revenues of CHF 1.1 million amid a significant decline of CHF 32.1 million year-over-year. The company holds CHF 246.6 million in cash, funding operations until Q1 2024. A Phase 1 trial with Eli Lilly for Morphomer™ Tau showed promising pharmacokinetics, while the TDP-43 therapeutic program advances with EU grant support. However, a Phase 2 trial of the anti-Tau antibody did not meet primary efficacy endpoints. R&D expenditures increased by over 35%, and the net loss for Q3 reached CHF 19 million.

AC Immune (NASDAQ: ACIU), a leading biopharmaceutical company focused on neurodegenerative diseases, announced its participation in the Jefferies Virtual London Healthcare Conference on November 18, 2020. CEO Prof. Andrea Pfeifer will discuss the company’s strategies for 2021, particularly its candidates targeting TAR DNA-binding protein 43 (TDP-43), which is critical in conditions like Alzheimer’s and amyotrophic lateral sclerosis (ALS). The presentation aims to highlight their innovative approach to precision medicine in treating these diseases.